MyMD Pharmaceuticals Enrolls First Client in Phase 2 Professional Test of MYMD-1 as a Therapy for Delaying Aging as well as Expanding Healthy And Balanced Life-span

MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals Inc – Stock Price, Quote and News (” MyMD” or “the Firm”), a scientific phase pharmaceutical business committed to prolonging healthy and balanced life expectancy, today revealed that the initial individual has actually been enlisted in the Company’s Stage 2 scientific test of lead candidate MYMD-1, a dental immune regulatory authority medication, as a therapy for postponing aging as well as expanding healthy life expectancy.

The primary endpoint for the Phase 2 double-blind, placebo-controlled scientific trial is to attain a reduction in the flowing levels of (TNF-α), lump death aspect receptor I (TNFRI) and IL-6. TNF-α and IL-6 are the healthy proteins in the body that cause inflammation and help trigger the procedure of aging. The secondary measures of the test will certainly be the safety and security, tolerability, and pharmacokinetics in this population of people.

” In a Phase 1 scientific test of MYMD-1, we demonstrated the medication’s statistically substantial efficiency in lowering levels of TNF-α, a key player in causing pathological aging, in the blood. The FDA has actually accepted TNF-α reduction as the key endpoint for our Stage 2 study, which we believe settings us well for a successful Phase 2 result,” said Chris Chapman, M.D., Head Of State, Supervisor and also Principal Medical Police Officer of MyMD. “The initiation of person registration in this research study advancements our mission to slow down the aging procedure, protect against loss of muscle mass cells in aging, restriction frailty, and prolong healthy life expectancy.”

MyMD has actually mentioned that there are no FDA-approved medications for treating aging disorders and expanding healthy lifespan people, a market expected to be at the very least $600 billion by 20251 according to a significant financial investment financial institution. TNF-α blockers are one of the most proposed drugs by earnings, a worldwide market of approximately $40 billion each year,2 and also, according to Nature Aging journal,3 a stagnation in maturing that would raise life span by one year deserves $38 trillion and by 10 years deserves $367 trillion.

Along with aging, MYMD-1’s unique action in controling the immune system and dealing with chronic swelling is being established for the therapy of autoimmune illness, including rheumatoid arthritis (RA), numerous sclerosis (MS), diabetes mellitus, and also inflammatory bowel illness.

” We plan to start creating procedures for a Phase 2 pilot study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman noted. “The rising frequency of rheumatoid joint inflammation and other autoimmune and inflammatory diseases are driving demand for TNF preventions like MYMD-1, as well as our company believe our orally administered drug with very reduced toxicity would be disruptive to the $60 billion market for RA if approved by the FDA for this indicator.”

Rheumatoid joint inflammation influences approximately 40 million people worldwide.4.

About MYMD-1.

Initially created for autoimmune diseases, MYMD-1’s main function is to slow the aging procedure, protect against sarcopenia and also frailty, and also expand healthy life-span. Due to the fact that it can cross the blood-brain obstacle and get to the central nerve system (CNS), MYMD-1 is additionally placed to be a possible therapy for brain-related problems. Its device of activity and also efficiency in conditions consisting of several sclerosis (MS) and also thyroiditis have been researched through cooperations with numerous scholastic organizations. MYMD-1 is likewise showing promise in pre-clinical researches as a prospective therapy for message- COVID-19 problems and as an anti-fibrotic and also anti-proliferation healing.

MYMD-1 has revealed performance in pre-clinical researches in managing the body immune system by executing as a discerning prevention of tumor death factor-alpha (TNF-α), a motorist of persistent inflammation. Unlike various other treatments, MYMD-1 has been shown in these pre-clinical researches to selectively obstruct TNF-α when it comes to be overactivated in autoimmune conditions and also cytokine tornados, however not block it from doing its typical job of being a first responder to any type of regular type of modest infection. MYMD-1’s ease of dental dosing is another differentiator contrasted to presently available TNF-α blockers, every one of which require shipment by injection or infusion. No approved TNF inhibitor has actually ever been dosed by mouth. Additionally, the medication is not immunosuppressive and has not been shown to create the severe adverse effects usual with traditional therapies that deal with swelling.

Concerning MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a scientific stage pharmaceutical company committed to expanding healthy life-span, is concentrated on developing 2 unique therapeutic platforms that treat the root causes of disease as opposed to just dealing with the signs and symptoms. MYMD-1 is a drug platform based on a professional stage little molecule that regulates the body immune system to control TNF-α, which drives persistent swelling, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being established to delay aging, rise longevity, and treat autoimmune conditions and COVID-19- connected anxiety. The Firm’s 2nd drug system, Supera-CBD, is being established to deal with persistent discomfort, dependency as well as epilepsy. Supera-CBD is a novel artificial derivative of cannabidiol (CBD) and also is being developed to attend to and also improve upon the rapidly expanding CBD market, which includes both FDA authorized medications as well as CBD items not presently controlled as medicines. For more information, see www.mymd.com.